Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Humans
Antibodies, Monoclonal, Humanized
/ therapeutic use
Skin Neoplasms
/ drug therapy
Male
Female
Aged
Carcinoma, Squamous Cell
/ drug therapy
Middle Aged
Aged, 80 and over
Immune Checkpoint Inhibitors
/ therapeutic use
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Follow-Up Studies
Chemoradiotherapy
/ methods
Cemiplimab discontinuation
Cutaneous squamous cell carcinoma
Immunotherapy
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
received:
28
02
2024
accepted:
05
04
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
epublish
Résumé
In a princeps study we conducted in patients with advanced cutaneous squamous cell carcinoma treated with concomitant anti-Programmed cell death protein 1 (PD-1) and radiotherapy, we demonstrated a clinico radiological response to cemiplimab that appeared to persist over time, 1 year after treatment discontinuation. We conducted a single-center descriptive study at Caen Hospital from September 1, 2021 to September 2023, in 14 patients with advanced carcinoma treated with cemiplimab until September 1, 2021. The aim of this update is to examine clinical and radiological follow-up 2 years after discontinuation of cemiplimab. Of the 12 patients with a partial or complete response, we report 8 (66.7%) persistent responses 2 years after stopping cemiplimab, with only 2 patients progressing to distant disease, one lost to follow-up, and one death a priori unrelated to the disease. Our study confirms a long-term and persistent effect despite discontinuation of cemiplimab at least up to 2 years later.
Sections du résumé
BACKGROUND
BACKGROUND
In a princeps study we conducted in patients with advanced cutaneous squamous cell carcinoma treated with concomitant anti-Programmed cell death protein 1 (PD-1) and radiotherapy, we demonstrated a clinico radiological response to cemiplimab that appeared to persist over time, 1 year after treatment discontinuation.
METHOD
METHODS
We conducted a single-center descriptive study at Caen Hospital from September 1, 2021 to September 2023, in 14 patients with advanced carcinoma treated with cemiplimab until September 1, 2021. The aim of this update is to examine clinical and radiological follow-up 2 years after discontinuation of cemiplimab.
RESULTS
RESULTS
Of the 12 patients with a partial or complete response, we report 8 (66.7%) persistent responses 2 years after stopping cemiplimab, with only 2 patients progressing to distant disease, one lost to follow-up, and one death a priori unrelated to the disease.
CONCLUSION
CONCLUSIONS
Our study confirms a long-term and persistent effect despite discontinuation of cemiplimab at least up to 2 years later.
Identifiants
pubmed: 38713217
doi: 10.1007/s00262-024-03700-x
pii: 10.1007/s00262-024-03700-x
doi:
Substances chimiques
cemiplimab
6QVL057INT
Antibodies, Monoclonal, Humanized
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
PDCD1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118Informations de copyright
© 2024. The Author(s).
Références
Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Van Akkooi A, Bataille V et al (2023) European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. Treatment–Update 2023. Eur J Cancer 193:113252. https://doi.org/10.1016/j.ejca.2023.113252 . Epub 2023 Jul 28. PMID: 37708630
Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R et al (2020) Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer 138:125–132. https://doi.org/10.1016/j.ejca.2020.07.029 . (Epub 2020 Aug 31 PMID: 32882466)
doi: 10.1016/j.ejca.2020.07.029
pubmed: 32882466
Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P et al (2021) Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI Study Group. Cancers (Basel) 13(14):3547. https://doi.org/10.3390/cancers13143547.PMID:34298764;PMCID:PMC8305372
doi: 10.3390/cancers13143547.PMID:34298764;PMCID:PMC8305372
pubmed: 34298764
Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, et al (2022) Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer 157:250–258. https://doi.org/10.1016/j.ejca.2021.08.018 . Epub 2021 Sep 15. Erratum in: Eur J Cancer 166:309–310. PMID: 34536948
Bailly-Caillé B, Kottler D, Morello R, Lecornu M, Kao W, Meyer E et al (2023) Real-life study of the benefit of concomitant radiotherapy with cemiplimab in advanced cutaneous squamous cell carcinoma (cSCC): a retrospective cohort study. Cancers (Basel) 15(2):495. https://doi.org/10.3390/cancers15020495.PMID:36672444;PMCID:PMC9856754
doi: 10.3390/cancers15020495.PMID:36672444;PMCID:PMC9856754
pubmed: 36672444
Presley CJ, Gomes F, Burd CE, Kanesvaran R, Wong ML (2021) Immunotherapy in older adults with cancer. J Clin Oncol. 39(19):2115–2127. https://doi.org/10.1200/JCO.21.00138 . Epub 2021 May 27. PMID: 34043444; PMCID: PMC8260908
Migden MR, Schmults C, Khushanlani N, Guminski A, Chang AL, Lewis K et al (2022) 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Ann Oncol 33:S918–S919. https://doi.org/10.1016/j.annonc.2022.07.940 .
Gerard E, Lebbe C, Lanoy E, Quereux G, Bernard P, Viguier MA et al.(2023) 1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA. Ann Oncol 34:S683. https://doi.org/10.1016/j.annonc.2023.09.2274 .
Yushak ML, Lawson DH, Goings M, Mckellar M, Maynard N, Woodruff KS et al. (2019) Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: an updated analysis. J Clin Oncol. 37(15_suppl):e21015‑e21015. https://doi.org/10.1200/JCO.2019.37.15_suppl.e21015 .
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ et al. (2022) Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 387(17):1557–1568. https://doi.org/10.1056/NEJMoa2209813 . Epub 2022 Sep 12. PMID: 36094839; PMCID: PMC9844515.
Tachiki LML, Hippe DS, Williams Silva K, Hall ET, McCamy W, Fritzsche D et al. (2023) Bhatia S. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunol Immunother 72(11):3839–3850. https://doi.org/10.1007/s00262-023-03539-8 . Epub 2023 Sep 21. Erratum in: Cancer Immunol Immunother 72(12):4471. PMID: 37733060; PMCID: PMC10576731
Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V et al. (2023) European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: diagnostics and prevention-Update 2023. Eur J Cancer 193:113251. https://doi.org/10.1016/j.ejca.2023.113251 . Epub 2023 Jul 28. PMID: 37717283
Ruiz ES, Kus KJB, Smile TD, Murad F, Zhou G, Ilori EO et al (2022) Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: a dual-center retrospective study. J Am Acad Dermatol 87(1):87–94. https://doi.org/10.1016/j.jaad.2022.03.044 . (Epub 2022 Mar 29 PMID: 35364211)
doi: 10.1016/j.jaad.2022.03.044
pubmed: 35364211
Kim Y, Lehrer EJ, Wirth PJ, Khesroh EA, Brewer JD, Billingsley EM et al (2022Jun) Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis. J Am Acad Dermatol 86(6):1246–1257. https://doi.org/10.1016/j.jaad.2021.11.059 . (Epub 2021 Dec 7 PMID: 34890701)
doi: 10.1016/j.jaad.2021.11.059
pubmed: 34890701